Nicoderm CQ Disease Interactions
There are 8 disease interactions with Nicoderm CQ (nicotine).
Nicotine (applies to Nicoderm CQ) CVD/PVD
Major Potential Hazard, Moderate plausibility. Applicable conditions: Ischemic Heart Disease, Peripheral Arterial Disease, Arrhythmias
Nicotine has dose-dependent cardiovascular effects. At dosages used for smoking cessation, nicotine may produce peripheral vasoconstriction and increase heart rate, myocardial contractility and blood pressure. Although these effects are relatively minor and clinically insignificant in most healthy individuals, complications may occasionally occur in patients with underlying cardiovascular disease, particularly if they continue to smoke during nicotine therapy. Therapy with nicotine should be administered cautiously in patients with coronary artery disease, cardiac arrhythmias, and peripheral vascular disease. In general, nicotine therapy should be avoided during the immediate postmyocardial infarction period, in severe or worsening angina, and in life-threatening arrhythmias. All patients should stop smoking completely during nicotine replacement therapy.
Nicotine (applies to Nicoderm CQ) pheochromocytoma
Major Potential Hazard, Moderate plausibility.
Nicotine causes the release of catecholamines from the adrenal medulla. Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas. Therapy with nicotine should be administered cautiously in patients with these tumors.
Nicotine (applies to Nicoderm CQ) diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
Nicotine causes the release of catecholamines from the adrenal medulla, which can stimulate glycogenolysis. Patients with diabetes mellitus should be monitored more closely during therapy with nicotine, and their antidiabetic regimen adjusted accordingly.
Nicotine (applies to Nicoderm CQ) hyperthyroidism
Moderate Potential Hazard, Moderate plausibility.
Nicotine causes the release of catecholamines from the adrenal medulla, which can exacerbate the sympathetic nervous system manifestations of hyperthyroidism such as tachycardia, angina, and heart failure. Therapy with nicotine should be administered cautiously in patients with hyperthyroidism.
Nicotine (applies to Nicoderm CQ) liver disease
Moderate Potential Hazard, Moderate plausibility.
Nicotine is primarily metabolized by the liver, and systemic clearance is dependent on liver blood flow. Although data are lacking, impairment of liver function is likely to reduce nicotine clearance to some extent. Patients with liver disease using a nicotine product should be monitored for development of undue adverse effects and signs of nicotine toxicity, including nausea, salivation, cold sweat, palpitation, abdominal pain, diarrhea, headache, dizziness, vomiting, auditory and vision disturbances, tremors, mental confusion, and weakness. If necessary, nicotine dosage should be reduced or the treatment discontinued.
Nicotine (applies to Nicoderm CQ) PUD
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Peptic Ulcer
Nicotine can delay healing in peptic ulcer disease. Therapy with nicotine should be administered cautiously in patients with peptic ulcers.
Nicotine (applies to Nicoderm CQ) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Moderate and severe renal impairment can affect the clearance of nicotine or its metabolites. Consider dose reduction and monitoring patients for adverse events (e.g., nausea, dizziness) associated with elevated levels of nicotine.
Nicotine NS (applies to Nicoderm CQ) asthma
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease
Nicotine inhalers have not been studied in patients with asthma or chronic pulmonary disease. Nicotine is an airway irritant and might cause bronchospasm, so this drug should be used with caution in patients with bronchospastic disease. Other forms of nicotine replacement might be preferable in patients with severe bronchospastic airway disease.
Nicoderm CQ drug interactions
There are 31 drug interactions with Nicoderm CQ (nicotine).
Nicoderm CQ alcohol/food interactions
There is 1 alcohol/food interaction with Nicoderm CQ (nicotine).
More about Nicoderm CQ (nicotine)
- Nicoderm CQ consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (63)
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: smoking cessation agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.